Storage of Polyvinylpyrrolidone (PVP) in Tissues Following Long‐Term Treatment with a PVP‐Containing Vasopressin Preparation
- 12 January 1978
- journal article
- research article
- Published by Wiley in Acta Medica Scandinavica
- Vol. 204 (1-6) , 295-298
- https://doi.org/10.1111/j.0954-6820.1978.tb08442.x
Abstract
The parenteral use of polyvinylpyrrolidone (PVP) leads to PVP retention in humans. Four case histories dealing with patients on long-term treatment with a PVP-containing vasopressin preparation are presented, and the possibility of a harmful effect of the PVP storage is discussed. The presence of PVP in serum, demonstrated by lipoprotein electrophoresis, is described. Based on the literature and the present findings, a withdrawal of PVP-containing preparations for injectional purposes is advocated.This publication has 5 references indexed in Scilit:
- Letter: Alkaline phosphatase levels in epileptic subjects.BMJ, 1974
- Quantitative plasma lipoprotein estimation by agarose gel electrophoresisClinica Chimica Acta; International Journal of Clinical Chemistry, 1970
- Excretion and Distribution of Polyvinyl Pyrrolidone in Man: As Determined by Use of Radiocarbon as a TracerAmerican Journal of Clinical Pathology, 1953
- Polyvinyl Pyrrolidone as a Plasma ExpanderNew England Journal of Medicine, 1952
- Speicherungserscheinungen beim Menschen nach PeristonKlinische Wochenschrift, 1952